Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfizer, Lilly To Revive Antibody Drug
by Ann M. Thayer
November 4, 2013
| A version of this story appeared in
Volume 91, Issue 44
Pfizer will work with Eli Lilly & Co. to continue development of tanezumab, a monoclonal antibody it developed for osteoarthritis, back pain, and cancer pain. In 2010, FDA put a partial hold on clinical development of tanezumab because of adverse side effects. FDA may allow trials to restart, pending Pfizer’s submission of nonclinical data in the first half of 2014. A payment by Lilly to Pfizer is contingent on a continuation of the collaboration after FDA responds to the data. Lilly also will make payments to Pfizer for achieving clinical, regulatory, and commercial milestones.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter